🇺🇸 FDA
Patent

US 12060555

MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis

granted A61KA61K31/713A61P

Quick answer

US patent 12060555 (MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis) held by UNIVERSITY OF CONNECTICUT expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
UNIVERSITY OF CONNECTICUT
Grant date
Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/713, A61P, A61P9/10